Novavax to Move Forward With Covid-19-Flu Vaccine

On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA ...
In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...
Under terms of the deal, the company and the UKHSA agreed to settle the outstanding amount under dispute related to upfront ...
Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) closed the latest trading day at $10.07, indicating a -1.76% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day.